Skip to main content
SpringerLink
Log in

Focus on New Drugs in Development Against Human Cytomegalovirus

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The limitations of current therapies for human cytomegalovirus (HCMV) coupled with the continued impact of HCMV disease in the immunocompromised host are the driving force for the development of new drugs against HCMV. This review predominantly focuses on new non-DNA polymerase inhibitors of HCMV replication. Drugs such as tomeglovir (BAY-384766), 2-bromo-5,6-dichloro-1- β-D-ribofuranosyl benzimidazole (BDCRB) and GW-275175X act as inhibitors of the terminase complex that is involved in cleavage and packaging of the unit length DNA into the capsids. Although the viral protein kinase UL97 has been exploited as an activator of ganciclovir and its prodrug valganciclovir, a new inhibitor maribavir (benzamidavir) has been shown to be a highly potent inhibitor of this enzyme. Many of these compounds have undergone successful phase I clinical trials. There are other compounds which have been identified through drug-screening but are at the earlier stages of development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Griffiths PD, Emery VC. Cytomegalovirus. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone, 1997: 445–70

    Google Scholar 

  2. Pillay D, Emery VC, Griffiths PD. Clinical aspects of treatment of cytomegalovirus. In: Jeffries DJ, DeClerq E, editors. Antiviral Chemotherapy. Chichester: Wileys, 1995: 265–83

    Google Scholar 

  3. Emery V, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97: 8039–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lowance D, Neumayer HH, Legendre C, et al. Valaciclovir reduces the incidence of cytomegalovirus disease and acute rejection in renal allograft recipients. N Engl J Med 1999; 340: 1462–70

    Article  CAS  PubMed  Google Scholar 

  5. Brown F, Banken L, Saywell K, et al. Pharmacokinetic of valganciclovir and follwoing multiple dosages of valganciclovir in HIV- and CMV- seropositive volunteers. Clin Pharmacokinet 1999; 37: 167–76

    Article  CAS  PubMed  Google Scholar 

  6. Pescovitz MD, Rabkin J, Merion RM, et al. Vlaganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44(10): 2811–5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sugawara M, Huang W, Fei YJ, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000; 89(6): 781–9

    Article  CAS  PubMed  Google Scholar 

  8. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184(11): 1461–4

    Article  CAS  PubMed  Google Scholar 

  9. Boivin G, Gilbert C, Gaudreau A, et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184(12): 1598–602

    Article  CAS  PubMed  Google Scholar 

  10. Underwood MR, Harvey RJ, Stanat S, et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 Gene Product. J Virol 1998; 72: 717–25

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Krosky PM, Underwood MR, Turk SR, et al. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 1998; 72: 4721–8

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Boyd F, Turner EM Freeman GA, et al. Synthesis and evaluation of a series of 1H-benzimidazole pyranosides as anti-human cytomegalovirus agents. Proceedings of the 218th ACS National Meeting; 1999 Aug 22–26; New Orleans (LA), USA

  13. Chulay J, Biron KK, Wang L, et al. Development of novel benzimidazole riboside compounds for treatment cytomegalovirus disease. Adv Exp Med Biol 1999; 458: 129–34

    Article  CAS  PubMed  Google Scholar 

  14. Zacny VL, Gershburg E, Davis MG, et al. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)- 1-beta-L-ribofuranosyl-1H benzamidazole. J Virol 1999; 73: 7271–7

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160–2

    Article  CAS  PubMed  Google Scholar 

  16. Eckenberg P, Reefschlaeger J, Bender W, et al. Structure-activity-relationships of BAY 38-4766 — a novel non-nucleosidic inhibitor of human cytomegalovirus replication [abstract no. 940]. Proceedings of the 39th ICAAC; 1999 Sep 26–29; San Francisco

  17. Reefschlaeger J, Bender W, Eckenberg P, et al. Antiviral activity and selectivity of BAY 38-4766 — a novel non-nucleosidic inhibitor of human cytomegalovirus replication [abstract no. 942]. Proceedings of the 39th ICAAC; 1999 Sep 26–29; San Francisco

  18. Hallenberger S, Trappe J, Buerger I, et al. Mechanism of antiviral action of BAY 38-4766 — a novel non-nucleosidic inhibitor of human cytomegalovirus replication [abstract no. 941]. Proceedings of the 39th ICAAC; 1999 Sep 26–29; San Francisco

  19. Kern A, Blombach M, Schmeer K, et al. In vivo metabolism in rat and dog of BAY 38-4766 — a novel non-nucleosidic inhibitor of human cytomegalovirus replication [abstract no. 943]. Proceedings of the 39th ICAAC; 1999 Sep 26–29; San Francisco

  20. Nagelschmitz J, Moeller JG, Stass H, et al. Safety, tolerability and pharmacokinetics of single oral doses of BAY 38-4766 — a novel, non-nucleosidic inhibitor of human cytomegalovirus (HCMV) replication — in healthy male subjects [abstract no. 945]. Proceedings of the 39th ICAAC; 1999 Sep 26–29; San Francisco

  21. Oien NL, Hopkins TA, Poorman RA, et al. Selective inhibition of herpesvirus DNA polymerases by novel 4-hydroxyquinolines [abstract no. 1855]. Proceedings of the 40th ICAAC; 2000 Sep 17–20; Toronto

  22. Martinez A, Esteban AI, Castro A, et al. Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine acyclonucleosides. J Med Chem 1999; 42: 1145–50

    Article  CAS  PubMed  Google Scholar 

  23. Martinez A, Gil C, Perez C, et al. Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. J Med Chem 2000; 43: 3218–25

    Article  CAS  PubMed  Google Scholar 

  24. Martinez A, Gil C, Perez C, et al. Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl) benzothiadiazine dioxide derivatives. J Med Chem 2000; 43: 3267–73

    Article  CAS  PubMed  Google Scholar 

  25. Vara Prasad JVN, Steinbaugh B, Booth R, et al. Tricyclic compounds as non-nucleoside inhibitors of human simplex virus replication in vitro [abstract no. 768]. Proceedings of the 40th ICAAC; 2000 Sep 17–20; Toronto

  26. Meyer AL, Bruening EE, Dunkle WE, et al. PD0084430: A non-nucleoside inhibitor of human cytomegalovirus replication in vitro [abstract no. 785]. Proceedings of the 40th ICAAC; 2000 Sep 17–20; Toronto

Download references

Author information

Authors and Affiliations

  1. Department of Virology, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2QG, UK

    Vincent C. Emery & Aycan F. Hassan-Walker

Authors
  1. Vincent C. Emery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aycan F. Hassan-Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent C. Emery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Emery, V.C., Hassan-Walker, A.F. Focus on New Drugs in Development Against Human Cytomegalovirus. Drugs 62, 1853–1858 (2002). https://doi.org/10.2165/00003495-200262130-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262130-00002

Keywords

Search

Navigation